Dickerson Faith, Stallings Cassie, Origoni Andrea, Boronow John, Yolken Robert
Stanley Research Center at Sheppard Pratt, Sheppard Pratt Health System, 6501 North Charles, St., Baltimore, MD 21204, USA.
Schizophr Res. 2007 Jul;93(1-3):261-5. doi: 10.1016/j.schres.2007.03.022. Epub 2007 May 8.
We investigated the association between serum levels of C-reactive protein (CRP), a marker of inflammation, and the severity of psychopathology and cognitive impairment in schizophrenia.
We measured the levels of CRP in N=413 individuals with schizophrenia. Symptom severity was evaluated with the Positive and Negative Syndrome Scale (PANSS) and cognitive functioning with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
The individuals with CRP >or=5.0 mg/microl had significantly lower RBANS cognitive scores than those with CRP <5.0 mg/microl (F=8.07, p<.005). However the CRP groups did not differ in the severity of positive, negative, or general PANSS symptoms (all p>.2).
Elevated serum levels of C-reactive protein in schizophrenia are associated with the severity of cognitive impairment but not of psychiatric symptoms. The long term consequences of elevated levels of CRP require further investigation.
我们研究了炎症标志物血清C反应蛋白（CRP）水平与精神分裂症精神病理学严重程度及认知障碍之间的关联。
我们测量了413例精神分裂症患者的CRP水平。采用阳性和阴性症状量表（PANSS）评估症状严重程度，采用可重复性神经心理状态评估量表（RBANS）评估认知功能。
CRP≥5.0mg/μl的患者RBANS认知得分显著低于CRP<5.0mg/μl的患者（F=8.07，p<.005）。然而，CRP分组在PANSS阳性、阴性或一般症状的严重程度上并无差异（所有p>.2）。
精神分裂症患者血清C反应蛋白水平升高与认知障碍的严重程度相关，但与精神症状无关。CRP水平升高的长期后果需要进一步研究。
